ADSE requires prior authorization for nearly half of cancer treatments

Starting Thursday, October 1, the number of oncological drugs requiring prior authorization from ADSE will be 196, covering 49% of subsidized treatments. This follows recent reductions in the reimbursement rates paid by the system to private healthcare providers.